Zeneca shares soar on back of merger rumours
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SHARES in Zeneca, the pharmaceuticals giant, surged by more than 4 per cent yesterday on speculation that it was likely to link up with Astra, Sweden's largest drugs group.
Astra said yesterday that it was in talks about "restructuring" its American sales joint venture with Merck, the US group, paving the way for a strategic merger with another company.
The deal, likely to be announced next week, could see Astra paying Merck $15bn (pounds 9bn) for the 50 per cent of the joint venture it does not own. Payments are likely to be linked to future drug sales and to be spread over several years.
The agreement would remove a hurdle that has prevented other pharmaceuticals companies from linking up with Astra in the past. Under the terms of the 16-year-old deal, Merck has first refusal to sell any Astra product in the key United States market.
In March, Hakan Mogren, Astra's chief executive, publicly named Zeneca, Germany's Bayer, and Schering Plough of the US as attractive potential partners.
Astra's main attraction is the anti-ulcer drug Losec, the world's largest- selling prescription medicine. But patents on the drug begin to expire next year.
Zeneca shares rose by 110p to 2628p yesterday.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments